心房細動の市場規模、シェア、成長分析：治療タイプ別、最終用途別、地域別 - 産業予測 2025～2032年

心房細動市場規模は2023年に233億1,000万米ドルと評価され、2024年の258億5,000万米ドルから2032年には591億5,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは10.9%で成長する見通しです。

心房細動市場は、特に高齢化社会における罹患率の上昇と、カテーテルアブレーションなどの治療技術の進歩により、大きな成長を遂げています。現在、米国では65歳未満の約2％、65歳以上の約9％が心房細動と診断されており、2050年には米国で600万～1,600万人、欧州では2060年までに900万～1,400万人に急増すると予測されています。しかし、専門医の不足や治療費の高騰など、市場の課題は依然として残っています。レーザーや高周波の応用など、新しい治療法の統合は課題であると同時にチャンスでもあります。また、薬と機器の相乗効果によって治療成績が向上し、市場のさらなる拡大が期待されます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術の進歩

心房細動市場規模：治療タイプ別& CAGR（2025-2032）

• 市場概要
• 薬物治療
  • 抗不整脈薬
  • 抗凝固薬
• 非薬物治療
  • カテーテルアブレーション
  • ラジオ波焼灼療法
  • HIFU
  • 凍結療法
  • マイクロ波治療
  • レーザー
  • メイズ手術
  • 電気的除細動

心房細動市場規模：最終用途別& CAGR（2025-2032）

• 市場概要
• 病院
• 専門クリニック
• その他

心房細動市場規模& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Johnson & Johnson（USA）
• Abbott Laboratories（USA）
• Medtronic plc（Ireland）
• Boston Scientific Corporation（USA）
• AtriCure Inc.（USA）
• MicroPort Scientific Corporation（China）
• Koninklijke Philips N.V.（Netherlands）
• Biotronik SE & Co. KG（Germany）
• Siemens AG（Germany）
• Boehringer Ingelheim GmbH（Germany）
• Sanofi-Aventis（France）
• Bristol-Myers Squibb Company（USA）
• CardioFocus Inc.（USA）
• Biosense Webster Inc.（USA）
• Endoscopic Technologies Inc.（USA）
• St. Jude Medical（USA）
• AliveCor, Inc.（USA）
• Milestone Pharmaceuticals Inc.（Canada）

結論と提言

Atrial Fibrillation Market size was valued at USD 23.31 billion in 2023 and is poised to grow from USD 25.85 billion in 2024 to USD 59.15 billion by 2032, growing at a CAGR of 10.9% during the forecast period (2025-2032).

The atrial fibrillation (AFib) market is witnessing significant growth, driven by rising incidence rates, particularly among the aging population, and advancements in treatment technologies like catheter ablation. Currently, about 2% of individuals under 65 and nearly 9% of those over 65 in the U.S. are diagnosed with AFib, with projections indicating that cases could soar to between 6-16 million by 2050 in the U.S. and from 9 million to 14 million in Europe by 2060. However, market challenges, including a shortage of specialists and the high costs of treatment, persist. The integration of novel therapies, such as laser and radiofrequency applications, poses both a challenge and opportunity, as do synergies between medications and devices that could enhance management outcomes and stimulate further market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Atrial Fibrillation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Atrial Fibrillation Market Segments Analysis

Global Atrial Fibrillation Market is segmented by Treatment type, End-Use and region. Based on Treatment type, the market is segmented into Pharmacological Treatment and Non-Pharmacological Treatment. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Atrial Fibrillation Market

The atrial fibrillation market is primarily driven by the increasing aging population, which is particularly susceptible to this condition. According to the World Health Organization (WHO), by 2030, roughly one in six people worldwide will be aged 60 or older, indicating a significant demographic shift. The number of individuals in this age group is projected to grow from 1 billion in 2020 to 1.4 billion in 2030, and by 2050, it is expected to reach 2.1 billion. Moreover, there will be a substantial rise in the population aged 80 and above, with estimates suggesting a threefold increase to 426 million by 2050. This demographic trend highlights the urgent need for effective treatments and management strategies for atrial fibrillation as the population ages.

Restraints in the Atrial Fibrillation Market

The substantial expenses associated with treating atrial fibrillation represent a significant obstacle to the advancement of the atrial fibrillation market. According to research from Science Direction, the average hospitalization cost per patient is approximately USD 3,530 (with a 95% confidence interval of $3,328 to $3,732), while outpatient facility visits average around USD 3,878 (with a 95% confidence interval of $3,769 to $3,987). Additionally, emergency room visits incur an average charge of $394 (with a 95% confidence interval of $358 to $430). These high treatment costs are likely to impede the growth of the atrial fibrillation market significantly.

Market Trends of the Atrial Fibrillation Market

The atrial fibrillation (AFib) market is witnessing significant growth driven by the rising prevalence of the condition, which currently affects approximately 37.57 million individuals worldwide. The National Institutes of Health reports a 33% increase in incidence over the past two decades, highlighting a concerning trend, particularly in countries with middle socio-demographic indices. Modern lifestyle factors, including obesity, hypertension, and diabetes, are exacerbating the situation, further contributing to the market's expansion. As healthcare systems adapt to manage this growing demand, the AFib market is poised for innovation, with an increase in treatment options, diagnostic tools, and patient management solutions emerging as key trends.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement

Global Atrial Fibrillation Market Size by Treatment type & CAGR (2025-2032)

• Market Overview
• Pharmacological Treatment
  • Anti-arrhythmic Drugs
  • Anticoagulant Drugs
• Non-Pharmacological Treatment
  • Catheter Ablation
  • Radiofrequency
  • HIFU
  • Cryoablation
  • Microwave
  • Laser
  • Maze Surgery
  • Electric Cardioversion

Global Atrial Fibrillation Market Size by End-Use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Others

Global Atrial Fibrillation Market Size & CAGR (2025-2032)

• North America (Treatment type, End-Use)
  • US
  • Canada
• Europe (Treatment type, End-Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment type, End-Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment type, End-Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment type, End-Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AtriCure Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPort Scientific Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotronik SE & Co. KG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi-Aventis (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CardioFocus Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biosense Webster Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endoscopic Technologies Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• St. Jude Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AliveCor, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Milestone Pharmaceuticals Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations